Dr. Dulai is a a physician-scientist with clinical expertise in inflammatory bowel disease and research expertise in clinical trial methodology and design, biomarker discovery, and multi-omic multi-dimensional data integration to study immune mediated inflammatory diseases. He completed his internal medicine residency and chief residency at Dartmouth and subsequently completed a 3-year NIH sponsored T32 research fellowship and a 1-year IBD clinical fellowship at the University of California San Diego. He completed a clinical trials fellowship at Robarts Clinical Trials (now Alimentiv). He has embarked into the field of human-translational research with a specific focus on integrating evolving technology and methodology to study immune-microbe interactions in the context of therapeutic interventions. His goal is to provide a growing framework for how we in the field of IBD can begin to develop and validate companion tools and/or biomarkers for disease prognosis, treatment prediction, and drug development programs.